Cargando…

Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis

BACKGROUND: Stage II colorectal cancer with microsatellite instability-high (MSI-H) has been proven to have a better prognosis. However, in advanced stage, this trend remains controversial. This study aimed to explore the prognostic role of MSI-H in stage III and IV colorectal cancer (CRC) through m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bingyan, Li, Fei, Zhou, Xin, Ma, Yanpeng, Fu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805421/
https://www.ncbi.nlm.nih.gov/pubmed/31639018
http://dx.doi.org/10.1186/s12957-019-1706-5
_version_ 1783461380080271360
author Wang, Bingyan
Li, Fei
Zhou, Xin
Ma, Yanpeng
Fu, Wei
author_facet Wang, Bingyan
Li, Fei
Zhou, Xin
Ma, Yanpeng
Fu, Wei
author_sort Wang, Bingyan
collection PubMed
description BACKGROUND: Stage II colorectal cancer with microsatellite instability-high (MSI-H) has been proven to have a better prognosis. However, in advanced stage, this trend remains controversial. This study aimed to explore the prognostic role of MSI-H in stage III and IV colorectal cancer (CRC) through meta-analysis. METHODS: A comprehensive search was performed in PubMed, Cochrane Central Library, and Embase databases. All randomized clinical trials and non-randomized studies were included based on inclusion and exclusion criteria and on survival after a radical operation with or without chemotherapy. The adjusted log hazard ratios (HRs) were used to estimate the prognostic value between MSI-H and microsatellite-stable CRCs. The random-effects model was used to estimate the pooled effect size. RESULTS: Thirty-six studies were included. Randomized controlled trials (RCT) and non-RCT were analyzed separately. For stage III CRCs, pooled HR for overall survival (OS) was 0.96 (95% confidence interval [CI] 0.75–.123) in the RCT subgroup and 0.89 (95% CI 0.62–1.28) in the non-RCT subgroup. For disease-free survival (DFS), the HR for the RCT group was 0.83 (95% CI 0.65–1.07), similar to the non-RCT subgroup (0.83, 95% CI 0.65–1.07). Disease-specific survival (DSS) was also calculated, which had an HR of 1.07 (95% CI 0.68–1.69) in the non-RCT subgroup. All these results showed that MSI-H has no beneficial effects in stage III CRC. For stage IV CRC, the HR for OS in the RCT subgroup was 1.23 (95% CI 0.92–1.64) but only two RCTs were included. For non-RCT study, the combined HR for OS and DFS was 1.10 (95% CI 0.77–1.51) and 0.72 (95% CI 0.53–0.98), respectively, suggesting the beneficial effect for DFS and non-beneficial effect for OS. CONCLUSION: For stage III CRC, MSI-H had no prognostic effect for OS, DFS, and DSS. For stage IV CRC, DFS showed a beneficial result, whereas OS did not; however, the included studies were limited and needed further exploration.
format Online
Article
Text
id pubmed-6805421
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68054212019-10-24 Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis Wang, Bingyan Li, Fei Zhou, Xin Ma, Yanpeng Fu, Wei World J Surg Oncol Review BACKGROUND: Stage II colorectal cancer with microsatellite instability-high (MSI-H) has been proven to have a better prognosis. However, in advanced stage, this trend remains controversial. This study aimed to explore the prognostic role of MSI-H in stage III and IV colorectal cancer (CRC) through meta-analysis. METHODS: A comprehensive search was performed in PubMed, Cochrane Central Library, and Embase databases. All randomized clinical trials and non-randomized studies were included based on inclusion and exclusion criteria and on survival after a radical operation with or without chemotherapy. The adjusted log hazard ratios (HRs) were used to estimate the prognostic value between MSI-H and microsatellite-stable CRCs. The random-effects model was used to estimate the pooled effect size. RESULTS: Thirty-six studies were included. Randomized controlled trials (RCT) and non-RCT were analyzed separately. For stage III CRCs, pooled HR for overall survival (OS) was 0.96 (95% confidence interval [CI] 0.75–.123) in the RCT subgroup and 0.89 (95% CI 0.62–1.28) in the non-RCT subgroup. For disease-free survival (DFS), the HR for the RCT group was 0.83 (95% CI 0.65–1.07), similar to the non-RCT subgroup (0.83, 95% CI 0.65–1.07). Disease-specific survival (DSS) was also calculated, which had an HR of 1.07 (95% CI 0.68–1.69) in the non-RCT subgroup. All these results showed that MSI-H has no beneficial effects in stage III CRC. For stage IV CRC, the HR for OS in the RCT subgroup was 1.23 (95% CI 0.92–1.64) but only two RCTs were included. For non-RCT study, the combined HR for OS and DFS was 1.10 (95% CI 0.77–1.51) and 0.72 (95% CI 0.53–0.98), respectively, suggesting the beneficial effect for DFS and non-beneficial effect for OS. CONCLUSION: For stage III CRC, MSI-H had no prognostic effect for OS, DFS, and DSS. For stage IV CRC, DFS showed a beneficial result, whereas OS did not; however, the included studies were limited and needed further exploration. BioMed Central 2019-10-21 /pmc/articles/PMC6805421/ /pubmed/31639018 http://dx.doi.org/10.1186/s12957-019-1706-5 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wang, Bingyan
Li, Fei
Zhou, Xin
Ma, Yanpeng
Fu, Wei
Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis
title Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis
title_full Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis
title_fullStr Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis
title_full_unstemmed Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis
title_short Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis
title_sort is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? a meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805421/
https://www.ncbi.nlm.nih.gov/pubmed/31639018
http://dx.doi.org/10.1186/s12957-019-1706-5
work_keys_str_mv AT wangbingyan ismicrosatelliteinstabilityhighreallyafavorableprognosticfactorforadvancedcolorectalcancerametaanalysis
AT lifei ismicrosatelliteinstabilityhighreallyafavorableprognosticfactorforadvancedcolorectalcancerametaanalysis
AT zhouxin ismicrosatelliteinstabilityhighreallyafavorableprognosticfactorforadvancedcolorectalcancerametaanalysis
AT mayanpeng ismicrosatelliteinstabilityhighreallyafavorableprognosticfactorforadvancedcolorectalcancerametaanalysis
AT fuwei ismicrosatelliteinstabilityhighreallyafavorableprognosticfactorforadvancedcolorectalcancerametaanalysis